Related Experiment Video

Updated: Jul 5, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V

Sarah Seiler1, Axel Schlitt, Xian-Cheng Jiang

  • 1Department of Medicine IV, Saarland University, Homburg/Saar, Germany. Sarahseiler@gmx.de

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|May 27, 2008
PubMed

Insights

In chronic kidney disease (CKD) patients, high cholesteryl ester transfer protein (CETP) activity and low HDL-cholesterol did not increase cardiovascular event risk. CETP inhibitors may not benefit these patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Lipidology

Background:

  • Patients with chronic kidney disease (CKD) face a higher risk of cardiovascular events (CVE).
  • Uraemic dyslipidaemia, characterized by low HDL-cholesterol (HDL-C) and high triglycerides, contributes to this risk.
  • Cholesteryl ester transfer protein (CETP) reduces HDL-C by transferring cholesterol esters.

Purpose of the Study:

  • To investigate the association between CETP activity and CVE in patients with CKD stage V.
  • To determine if CETP activity correlates with HDL-C levels in this population.

Main Methods:

  • Measured CETP activity and cholesterol levels in 69 haemodialysis patients.
  • Prospectively assessed CVE and death over a 48-month follow-up period.

Main Results:

  • CETP activity was negatively correlated with HDL-C in patients not on lipid-lowering medication (r = -0.379, P = 0.005).
  • No significant difference in CETP activity was observed between patients with and without cardiovascular disease at baseline or for incident CVE during follow-up.
  • Stratifying patients by median CETP activity or median HDL-C did not reveal an increased risk for CVE or death.

Conclusions:

  • Despite a correlation between CETP activity and HDL-C, neither high CETP activity nor low HDL-C was linked to CVE in CKD stage V patients.
  • Pharmacological modification of HDL-C using CETP inhibitors may have limited clinical value in this patient group.
Abstract

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...